With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...

The US Food and Drug Administration (FDA) has released a final guidance document with immediate effect advising sponsors on ...

In this webinar, Gonçalo Regalo discusses how raw materials, media composition, and process design influence scalable cell ...

There is no margin for error in the pharma and biopharma sectors. If the chain-identity breaks anywhere along the way, there ...

The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, ...

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...

Viralgen continues its pioneering work in manufacturing science with advancements in key process understanding with analytical tools ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th ...

Beta thalassemia major, also known as Cooley’s anemia and transfusion-dependent beta thalassemia, causes the body’s red blood ...